Barry R Davis
Affiliation: Texas Medical Center
- ALLHAT: setting the record straightBarry R Davis
The University of Texas Health Science Center at Houston School of Public Health, Houston, Texas 77030, USA
Ann Intern Med 141:39-46. 2004....
- Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment tBarry R Davis
The University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA
Ann Intern Med 137:313-20. 2002..Sixty-eight percent (6167 of 9061) of the former patients and 59% (9081 of 15 256) of the latter patients were given additional medications to achieve a target blood pressure of less than 140/90 mm Hg...
- Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses--a new method for the Genetics of Hypertension Associated Treatment (GenHAT) studyBarry R Davis
University of Texas School of Public Health, Houston, TX 77030, USA
Stat Med 23:2413-27. 2004....
- ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesJackson T Wright
ALLHAT Clinical Trials Center, University of Texas at Houston Health Science Center School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA
Arch Intern Med 169:832-42. 2009..Thiazides are superior in preventing HF, and new-onset DM associated with thiazides does not increase CVD outcomes...
- Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT studyAmy I Lynch
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama 55294 0022, USA
Pharmacogenet Genomics 22:355-66. 2012..The goal was to identify subgroups of individuals on the basis of their genetic profile who benefit most from a particular treatment...
- Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trialBarry R Davis
University of Texas Health Science Center School of Public Health, Houston, TX 77030, USA
Circulation 118:2259-67. 2008....
- Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Linda B Piller
University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 77030, USA
J Clin Hypertens (Greenwich) 8:649-56; quiz 657-8. 2006..One patient died following an angioedema episode. The occurrence of angioedema in the angiotensin-converting enzyme inhibitor arm corresponds with previously reported angioedema-angiotensin-converting enzyme inhibitor associations...
- Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Linda B Piller
University of Texas School of Public Health, Houston, TX 77030, USA
Circulation 124:1811-8. 2011..After the randomized phase of the trial ended in 2002, outcomes were determined from administrative databases...
- Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialBarry R Davis
The University of Texas School of Public Health, Houston, TX 77030, USA
Circulation 113:2201-10. 2006..The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF...
- Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and ChlorthalidoneLinda B Piller
The University of Texas School of Public Health, Houston, TX, USA
Curr Control Trials Cardiovasc Med 3:10. 2002..96; 95% CI, 0.67-1.38; P = 0.83). CONCLUSION: Results of the validation process supported findings of increased heart failure in the ALLHAT doxazosin treatment arm compared to the chlorthalidone treatment arm...
- Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHATLinda B Piller
The University of Texas School of Public Health, 1200 Herman Pressler St, W 906, Houston, TX, 77030, USA
J Gen Intern Med 29:1475-83. 2014..Hypertension is a major risk factor for peripheral artery disease (PAD). Little is known about relative efficacy of antihypertensive treatments for preventing PAD...
- Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHATJose Miguel Yamal
Coordinating Center for Clinical Trials, Division of Biostatistics, University of Texas School of Public Health, Houston, TX, USA Electronic address
J Am Soc Hypertens 8:808-19. 2014..These differences abated by the end of the post-trial period...
- Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHATEfrain Reisin
aSection of Nephrology and Hypertension, Louisiana State University Health Science Center, New Orleans, Louisiana bDivision of Nephrology Hypertension, Mayo Clinic, Rochester, Minnesota cCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, Texas dDivision of Endocrinology, Kaiser Permanente of Georgia and Emory University School of Medicine, Atlanta, Georgia eThe National Heart, Lung, and Blood Institute, Bethesda, Maryland fCenter for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin gHoward University Hypertension and Lipid Clinic, Howard University Hospital, Washington, District of Columbia hVeterans Affairs Medical Center and Wright State University Veterans Affairs Campus, Dayton, Ohio, USA
J Hypertens 32:1503-13; discussion 1513. 2014..9), and obese (BMI >30)]...
- Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination ProjectL Kay Bartholomew
University of Texas Health Science Center Houston, School of Public Health, Houston, TX, USA
Clin Trials 6:329-43. 2009..Conventional dissemination of clinical trial results has inconsistent impact on physician practices. A more comprehensive plan to influence determinants of prescribing practices is warranted...
- Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAJoshua I Barzilay
Kaiser Permanente of Georgia, USA
Arch Intern Med 166:2191-201. 2006....
- The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosisPaula T Einhorn
National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892 7936, USA
Am Heart J 153:42-53. 2007..However, questions have been raised regarding the validity of the HF diagnosis...
- Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) studyAnke Hilse Maitland-van der Zee
School of Public Health, University of Texas Health Science Center at Houston, 1200 Hermann Pressler, Houston TX, USA
Am Heart J 153:54-8. 2007....
- Antihypertensive medications and risk of diabetes mellitusJoshua I Barzilay
Kaiser Permanente of Georgia and the Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA
Curr Opin Nephrol Hypertens 16:256-60. 2007..We also examine the impact of the glucose-sparing effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on preventing cardiovascular disease...
- Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertensionAmy I Lynch
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
JAMA 299:296-307. 2008..The NPPA gene codes for the precursor of atrial natriuretic polypeptide, suggesting that NPPA may modulate the efficacy of some antihypertensive drugs...
- Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Jackson T Wright
Department of Medicine, General Clinical Research Center, Cleveland, Ohio, USA
Arch Intern Med 168:207-17. 2008....
- Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul A Heidenreich
VA Palo Alto Health Care System, Palo Alto, CA, USA
J Gen Intern Med 23:509-16. 2008..To evaluate the cost-effectiveness of first-line treatments for hypertension...
- Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly programAlpesh B Patel
Department of Medicine, UMDNJ Robert Wood Johnson Medical School, One Robert Wood Johnson Pl, PO Box 19, New Brunswick, NJ 08903 0019, USA
Stroke 39:1084-9. 2008..Incident stroke was significantly decreased by treatment in the Systolic Hypertension in Elderly Program (SHEP) Trial, but the reduction in fatal events was not statistically significant...
- Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous interventionJohn Kao
David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 1717, USA
Am J Cardiol 93:1347-50, A5. 2004....
- Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialFrans H H Leenen
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Hypertension 48:374-84. 2006..Some, but not all, of these differences may be explained by less effective blood pressure control in the lisinopril arm...
- Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9Mahboob Rahman
Am J Hypertens 19:656-7. 2006
- Angiotensin-converting-enzyme inhibitors and diuretics for hypertensionBarry R Davis
N Engl J Med 349:90-3; author reply 90-3. 2003
- Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)William C Cushman
J Clin Hypertens (Greenwich) 4:393-404. 2002..Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified...
- Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement TrialSatish Kenchaiah
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Am Heart J 148:356-64. 2004..Hypertension is a well-established risk factor for myocardial infarction (MI), but its prognostic importance in survivors of an acute MI is less clear...
- Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetesJohn B Kostis
UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903 0019, USA
Am J Cardiol 95:29-35. 2005..Subjects who had diabetes associated with chlorthalidone had no significant increase in CV events and had a better prognosis than did those who had preexisting diabetes...
- Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinoprilJackson T Wright
General Clinical Research Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
JAMA 293:1595-608. 2005..Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs)...
- Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Mahboob Rahman
Division of Nephrology and Hypertension, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA
Arch Intern Med 165:936-46. 2005....
- Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) studyDonna K Arnett
University of Minnesota, Division of Epidemiology, Minneapolis, USA
Circulation 111:3374-83. 2005....
- Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul K Whelton
Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA
Arch Intern Med 165:1401-9. 2005....
- Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) ProjectMarc A Pfeffer
Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 105:2341-6. 2002..Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data...
- Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rateMahboob Rahman
Case Western Reserve University, Cleveland, Ohio, USA
Ann Intern Med 144:172-80. 2006..Chronic kidney disease is common in older patients with hypertension...
- Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT studyJoshua I Barzilay
Division of Endocrinology, Kaiser Permanente of Georgia, Tucker, GA 30084, USA
J Clin Hypertens (Greenwich) 6:116-25. 2004....
- Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Circulation 106:1243-50. 2002..No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI...
- Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialVerghese Mathew
Mayo Clinic, Gonda 5 South MS 130, 200 First Street SW, Rochester, Minn 55905, USA
Circulation 109:476-80. 2004..The aim of this study was to determine the influence of diabetes on 9-month outcomes of patients undergoing PCI in the current era...
- The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialMahboob Rahman
Division of Hypertension, Case Western Reserve University, Cleveland, Ohio 44106, USA
Arch Intern Med 164:969-76. 2004..The prevalence of reduced glomerular filtration rate (GFR) in older hypertensive patients and the relationship between level of GFR and cardiovascular disease (CVD) and its risk factors are not well known...
- Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaquePatrick W Serruys
Thoraxcenter, Ba583, Erasmus MC, Rotterdam, Netherlands
Circulation 118:1172-82. 2008....
- Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Mahboob Rahman
Case Western Reserve University, University Hospitals of Cleveland Case Medical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA
Am J Kidney Dis 52:412-24. 2008..Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear...
- Analysis of survival data with missing measurements of a time-dependent binary covariateSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
J Biopharm Stat 13:253-70. 2003..An example from the Systolic Hypertension in the Elderly Program was used. Inference on the effect of systolic blood pressure on survival is strongly affected by the number and timing of systolic blood measurements...
- Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertensionJeffrey A Cutler
National Heart, Lung, and Blood Institute, Bethesda, MD, USA
Circulation 117:2691-704; discussion 2705. 2008
- Home use of automated external defibrillators for sudden cardiac arrestGust H Bardy
Seattle Institute for Cardiac Research, Seattle, WA 98103 4819, USA
N Engl J Med 358:1793-804. 2008..Consequently, home use of an automated external defibrillator (AED) might offer an opportunity to improve survival for patients at risk...
- The Society for Clinical Trials supports United States legislation mandating trials registration. Position paperKay Dickersin
Department of Community Health, Brown University, Providence, RI 02912, USA
Clin Trials 1:417-20. 2004..Standardized data and a unique identification number would be available for each registered trial...
- Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertensiAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
Pharmacogenet Genomics 18:651-6. 2008..High homocysteine blood concentrations predispose to coronary artery disease and statins influence homocysteine levels...